p.80 抽出テキスト

Kusumoto et al 2018 Bradycardia Clinical Practice Guidelines

Circulation. 2019;140:e382–e482. DOI: 10.1161/CIR.0000000000000628 August 20, 2019 e461 CLINICAL STATEMENTS AND GUIDELINES

S5.3.2.1-16.	 Cossu SF, Rothman SA, Chmielewski IL, et al. The effects of isoproterenol on the cardiac conduction system: site-specific dose dependence. J Cardiovasc Electrophysiol. 1997;8:847–53. S5.3.2.1-17.	 Nathanson MH, Miller H. The action of norepinephrine, epinephrine and isopropyl norepinephrine on the rhythmic function of the heart. Circulation. 1952;6:238–44. S5.3.2.1-18.	 MacGregor DA, Smith TE, Prielipp RC, et al. Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology. 2000;92:338–46. S5.3.2.1-19.	 Tisdale JE, Patel RV, Webb CR, et al. Proarrhythmic effects of intravenous vasopressors. Ann Pharmacother. 1995;29:269–81. S5.3.2.1-20.	 Morales-Cane I, Valverde-Leon MD, Rodriguez-Borrego MA. Epinephrine in cardiac arrest: systematic review and meta-analysis. Rev Lat Am Enfermagem. 24;2016:e2821. S5.3.2.1-21.	 Reiffel JA, Bigger JT Jr, Reid DS. The effect of atropine on sinus node function in adults with sinus bradycardia. Am J Cardiol. 1975;35:165. S5.3.2.1-22.	 Chadda KD, Lichstein E, Gupta PK, et al. Effects of atropine in patients with bradyarrhythmia complicating myocardial infarction. Usefulness of an optimum dose for overdrive. Am J Med. 1977;63:503–10. S5.3.2.1-23.	 Das G, Talmers FN, Weissler AM. New observations on the effects of atropine on the sinoatrial and atrioventricular nodes in man. Am J Cardiol. 1975;36:281–5. S5.3.2.1-24.	 Aghamohammadi H, Mehrabi S, Mohammad Ali Beigi F. Prevention of bradycardia by atropine sulfate during urological laparoscopic surgery: a randomized controlled trial. Urol J. 2009;6:92–5. S5.3.2.1-25.	 Ferrans VJ, Hibbs RG, Black WC, et al. Isoproterenol-induced myocardial necrosis. A histochemical and electron microscopic study. Am Heart J. 1964;68:71–90. S5.3.2.1-26.	 Kurland G, Williams J, Lewiston NJ. Fatal myocardial toxicity during continuous infusion intravenous isoproterenol therapy of asthma. J Allergy Clin Immunol. 1979;63:407–11. S5.3.2.1-27.	 Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support. 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122:S729–67. S5.3.2.1-28.	 Jaffe R, Rubinshtein R, Feigenberg Z, et al. Evaluation of isoproterenol in patients undergoing resuscitation for out-of-hospital asystolic cardiac arrest (the Israel Resuscitation with Isoproterenol Study Prospective Randomized Clinical Trial). Am J Cardiol. 2004;93:1407–9. a9. S5.3.2.1-29.	 Jaffe R, Weiss AT, Rosenheck S. Combined isoproterenol and epinephrine for the resuscitation of patients with cardiac asystole secondary to coronary artery disease. Am J Cardiol. 1996;77:194–5. S5.3.2.1-30.	 Brunner-La Rocca HP, Weilenmann D, Bracht C, et al. Relative

frequency of functional sympathetic and parasympathetic reinnervation after heart transplantation. J Heart Lung Transplant. 1998;17:725–8.

5.3.2.2. Therapy of Beta Blocker and Calcium Channel Blocker Mediated Bradycardia Attributable to SND or Atrioventricular Block S5.3.2.2-1.	 Howarth DM, Dawson AH, Smith AJ, et al. Calcium channel blocking drug overdose: an Australian series. Hum Exp Toxicol. 1994;13:161–6. S5.3.2.2-2.	 Ramoska EA, Spiller HA, Winter M, et al. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. Ann Emerg Med. 1993;22:196–200. S5.3.2.2-3.	 St-Onge M, Dube PA, Gosselin S, et al. Treatment for calcium channel blocker poisoning: a systematic review. Clin Toxicol (Phila). 2014;52:926–44. S5.3.2.2-4.	 Bailey B. Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review. J Toxicol Clin Toxicol. 2003;41:595–602. S5.3.2.2-5.	 Love JN, Sachdeva DK, Bessman ES, et al. A potential role for glucagon in the treatment of drug-induced symptomatic bradycardia. Chest. 1998;114:323–6. S5.3.2.2-6.	 Engebretsen KM, Kaczmarek KM, Morgan J, et al. High-dose

insulin therapy in beta-blocker and calcium channel-blocker poisoning. Clin Toxicol (Phila). 2011;49:277–83. S5.3.2.2-7.	 Woodward C, Pourmand A, Mazer-Amirshahi M. High dose insu-

lin therapy, an evidence based approach to beta blocker/calcium channel blocker toxicity. Daru. 2014;22:36. S5.3.2.2-8.	 Graudins A, Lee HM, Druda D. Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies. Br J Clin Pharmacol. 2016;81:453–61. S5.3.2.2-9.	 Lavonas EJ, Drennan IR, Gabrielli A, et al. Part 10: special circumstances of resuscitation: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132:S501–18. S5.3.2.2-10.	 Crump BJ, Holt DW, Vale JA. Lack of response to intravenous calcium in severe verapamil poisoning. Lancet. 1982;2:939–40. S5.3.2.2-11.	 Ghosh S, Sircar M. Calcium channel blocker overdose: Experience with amlodipine. Indian J Crit Care Med. 2008;12:190–3. S5.3.2.2-12.	 Henry M, Kay MM, Viccellio P. Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride. Am J Emerg Med. 1985;3:334–6. S5.3.2.2-13.	 St-Onge M, Anseeuw K, Cantrell FL, et al. Experts consensus recommendations for the management of calcium channel blocker Poisoning in Adults. Crit Care Med. 2017;45:e306–15. S5.3.2.2-14.	 Parmley WW. The role of glucagon in cardiac therapy. N Engl J Med. 1971;285:801–2. S5.3.2.2-15.	 Greene SL, Gawarammana I, Wood DM, et al. Relative safety of

hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study. Intensive Care Med. 2007;33:2019–24.

5.3.2.3. Therapy of Digoxin Mediated Bradycardia Attributable to either SND or Atrioventricular Block S5.3.2.3-1.	 Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81:1744–52. S5.3.2.3-2.	 Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol (Phila). 2014;52: 824–36. S5.3.2.3-3.	 Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol. 1991;17:590–8. S5.3.2.3-4.	 Lapostolle F, Borron SW, Verdier C, et al. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure. Intensive Care Med. 2008;34:1448–53. S5.3.2.3-5.	 Lapostolle F, Borron SW, Verdier C, et al. Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. Crit Care Med. 2008;36:3014–8. S5.3.2.3-6.	 Smith TW, Butler VP Jr, Haber E, et al. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: experience in 26 cases. N Engl J Med. 1982;307: 1357–62. S5.3.2.3-7.	 Wenger TL. Experience with digoxin immune Fab (ovine) in patients with renal impairment. Am J Emerg Med. 1991;9:21–3; discussion 33–4. S5.3.2.3-8.	 Wenger TL, Butler VP Jr, Haber E, et al. Treatment of 63 severely digitalis-toxic patients with digoxin-specific antibody fragments. J Am Coll Cardiol. 1985;5:118a–23a. S5.3.2.3-9.	 Mowry JB, Burdmann EA, Anseeuw K, et al. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin Toxicol (Phila). 2016;54:103–14. S5.3.2.3-10.	 Roberts DM, Gallapatthy G, Dunuwille A, et al. Pharmacological treatment of cardiac glycoside poisoning. Br J Clin Pharmacol. 2016;81:488–95. S5.3.2.3-11.	 Eddleston M, Rajapakse S, Rajakanthan, et al. Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. Lancet. 2000;355:967–72. S5.3.2.3-12.	 Caspi O, Zylber-Katz E, Gotsman O, et al. Digoxin intoxication in a patient with end-stage renal disease: efficacy of digoxin-specific Fab antibody fragments and peritoneal dialysis. Ther Drug Monit. 1997;19:510–5. S5.3.2.3-13.	 Putcha N, Allon M. Management of hyperkalemia in dialysis

patients. Semin Dial. 2007;20:431–9.

Downloaded from http://ahajournals.org by on October 7, 2026